OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Lisa LeCointe-Cephas, SVP, chief ethics and compliance officer and office of general counsel, human health, Merck, uses her unique style of leadership—stop, drop, and roll—while elevating voices that need to be heard.
Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Check out the latest issue of Pharmaceutical Executive!
September 30, 2023
EXXUA has been approved for treatment.
The company announced new hires for its chief scientific officer, chief business officer, and other leadership roles.
September 29, 2023
Korean-based company HoneyNaps developed the algorithm.
The proposed rule is aimed at ensuring the safety and effectiveness of the tests.
The program will offer participants more opportunity to communicate with FDA staff.
Rubin speaks about how drugs aren’t being properly valued.
September 28, 2023
Pombiliti + Opfolda indicated for adults who are not improving on current enzyme therapy.
Eye drop treatment indicated for pharmacologically induced mydriasis.
Deal comes amid first successful partnership.
Lakdawalla speaks about how drugs aren’t being properly valued.